Close Menu

NEW YORK – Takeda Pharmaceutical's mobocertinib has shown promising efficacy and safety in a Phase I/II trial in previously treated, advanced non-small cell lung cancer patients harboring EGFR exon 20 insertions. 

At the American Association for Cancer Research's Virtual Annual Meeting this week, Francois Gonzalvez, on behalf of Takeda, presented data showing that 43 percent of 28 mobocertinib-treated NSCLC patients with EGFR exon 20 insertions saw their tumors shrink and on average their tumors stopped progressing for around 7.3 months.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.


Join this webinar to learn how spatial resolution of gene expression in tumor tissue reveals new insights in biomarker discovery and therapeutic response. 


This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.


Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.